Generic drug giant spokesperson says resignation is effective immediately as Desai pursues other opportunities.
Apotex president and CEO Jeremy Desai resigned from the generic drug giant Friday while facing a lawsuit alleging he and the company accepted trade secrets leaked from a competitor.
The lawsuit from Teva Pharmaceutical Industries Limited. accuses Barinder Sandhu, who worked as a senior director of regulatory affairs for Teva’s U.S. generics division, of leaking trade secrets and other confidential information to Desai while being in a romantic relationship with him.
The allegations have not been proven in court and Apotex, Sandhu and Desai have filed motions to dismiss the complaint.
